Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma

Bai, Shilei; Yang, Pinghua; Xie, Zhenghua; Li, Jun; Lei, Zhengqing; Xia, Yong; Gao, Qian; Zhang, Baohua; Pawlik, Timothy M.; Lau, Wan Yee; Shen, Feng

doi:10.1245/s10434-021-09901-3

Cited by 20 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariate analyses of OS revealed a variable as independent prognostic factor: Child-Pugh class (B) in the HAIC with cisplatin cohort ( Table 2 A), on the other hand, three variables as independent prognostic factors: Child-Pugh class (B), higher serum ALBI levels, and higher serum AFP levels in the sorafenib cohort ( Table 2 B). It is well-known that the hepatic reserve factor and tumor factor contribute to OS of patients with HCC, which is consistent with the finding observed in the present study [ 23 , 24 , 25 ].…”

Section: Discussionsupporting

confidence: 93%

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Zaizen

Nakano

Fukumori

et al. 2021

Cancers

View full text Add to dashboard Cite

Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; p = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; p = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; p = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Zaizen

Nakano

Fukumori

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…HCCs with a high risk of microvascular invasion have shown poor prognosis after RFA. 366,521,522 However, since no RCT or meta-analysis has been performed yet, additional studies are needed.…”

Section: Rfamentioning

confidence: 99%

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

2022

Clin Mol Hepatol

169

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

show abstract

“…It is well known that the hepatic reserve factor and tumor factor contribute to OS of patients with HCC, which is consistent with the finding observed in the present study. [23][24][25] For managing intrahepatic advanced HCC, TACE or HAIC has been widely used for obtaining a higher antitumor effect as they evenly distribute the anticancer drug through the hepatic artery [26]. However, TACE involves inserting a microcatheter selectively into the tumor feeding artery; this requires high-level skills and adequate treatment time.…”

Section: Discussionmentioning

confidence: 99%

Hepatic Arterial Infusion Chemotherapy with Cisplatin Versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Zaizen¹,

Nakano²,

Fukumori³

et al. 2021

Preprint

View full text Add to dashboard Cite

Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 348 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 97) or sorafenib (n = 251) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 13.9 vs. 12.7 months; p = 0.0989). To reduce confounding effects, 176 patients were selected using propensity score-matched analysis (n = 88 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 16.2 vs. 12.2 months; p = 0.0060). Following stratification according to the Child–Pugh classification, for both patients with class A (MST: 24.0 vs. 15.6 months; p = 0.0097) and class B (MST: 8.5 vs. 6.9 months; p = 0.0391), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC, regardless of the hepatic reserve.

show abstract

Preoperative Estimated Risk of Microvascular Invasion is Associated with Prognostic Differences Following Liver Resection Versus Radiofrequency Ablation for Early Hepatitis B Virus-Related Hepatocellular Carcinoma

Cited by 20 publications

References 43 publications

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Hepatic Arterial Infusion Chemotherapy with Cisplatin Versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Contact Info

Product

Resources

About